Ranbaxy Laboratories Ltd, a leading pharmaceutical major, has announced that it has clinched an exclusive licensing pact with US-based BioPro Pharmaceutical to market Gliadel tablets in India.

Earlier, Ranbaxy had announced a similar agreement with CD Pharma, a leading Europe-based  biotech  firm to sell its probiotic dental medicine Inersan in India and  Nepal.

While commenting on the development, Sanjeev I Dani, senior vice president & regional director, Asia & CIS, Ranbaxy stated, “We are pleased to bring this lifesaving, high technology product to Indian patients. We are working with BioPro to create a productive relationship by complementing each other’s strengths. The licensing agreement, and subsequent launch approval, should enable Ranbaxy to further strengthen its position in the oncology segment.”

Gliadel is the only US Food and Drug Administration (USFDA) approved drug which is used during surgical resection, providing localized delivery of chemotherapy directly into the cavity created when a brain tumor is removed during surgery.